Analyst Price Target is $4.33
▲ +789.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Coeptis Therapeutics in the last 3 months. The average price target is $4.33, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 789.07% upside from the last price of $0.49.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Coeptis Therapeutics. This Buy consensus rating has held steady for over two years.
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.